Return to study ST001949 main page
MB Sample ID: SA183903
| Local Sample ID: | 21_021 |
| Subject ID: | SU002027 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Age Or Age Range: | 21 - 84 |
| Gender: | Male and female |
Select appropriate tab below to view additional metadata details:
Treatment:
| Treatment ID: | TR002039 |
| Treatment Summary: | Biobanked plasma samples were acquired from a subset of RA patients (n=20) that participated in a 16-week multicenter open-label study that sought to evaluated predictors of MTX response in RA (ClinicalTrials.gov NCT03414502) (PMID: 32911284). The study included sites within the Rheumatology Arthritis Investigational Network (RAIN). For each patient, plasma samples at baseline and 16-weeks were provided for analysis. All patients received 15 mg/week of MTX and 1 mg/day of folic acid upon enrollment. The MTX does was escalated to 20 mg/week in patients that did not achieve clinical remission by 8 weeks, as tolerated. |
| Treatment Compound: | Methotrexate |
| Treatment Route: | Subcutaneous or Oral |
| Treatment Dose: | 15-20 mg/week |
| Treatment Doseduration: | 16 weeks |
